pasritamig, KLK2 T-cell engager, bispecific antibody prostate cancer, Phase I trial results, mCRPC immunotherapy, Pasritamig Safety and Efficacy Data from Metastatic CRPC Phase I Study with Capucine ...

The prevalence of kidney stone disease and associated events is rising, with modern surgical approaches emphasizing minimally invasive techniques like ambulatory percutaneous nephrolithotomy (PCNL).

Neeraj Agarwal speaks with Praful Ravi about an individual patient data meta-analysis examining docetaxel addition to ADT plus radiation therapy in high-risk localized prostate cancer. The ISECaP ...

Zachary Klaassen discusses the NureCombo Trial with Chiara Mercinelli, examining neoadjuvant therapy for muscle-invasive bladder cancer. This phase II trial investigated nab-paclitaxel plus nivolumab ...

SNMMI 2025, post-177Lu therapy, WB SPECT/CT, WB SPECT/CT Studies Post Lu 177 Therapy, 177Lu-PSMA SPECT, StarGuide scanner, 177Lu-PSMA-617 radiopharmaceutical therapy.

PSMA and Beyond PSMA-targeted prostate biopsy, MRI-guided biopsy, PIRADS 2 lesion, 68Ga-PSMA-11, PSMA guided fusion biopsy, PIRADS delineation, SUVmax and PRIMARY score.

AUA 2025, Metastatic Renal Cell Carcinoma (mRCC), Maximal Evaluable Lesion Size in Patients with Metastatic Renal Cell Carcinoma, Nivolumab plus Ipilimumab Combination Therapy, nivolumab, ipilimumab, ...

PSMA and Beyond 2025 CA-IX in renal cell cancer (RCC), ZIRCON, kidney cancer, stage migration for RCC, REDECT trial, renal mass biopsy, girentuximab.

AUA 2025 Tokai Urologic Oncology Research Study (TOURS) database study, tyrosine kinase inhibitors (TKIs), immunotherapy (IO), advanced renal cell carcinoma (RCC).

Risk factors for low-risk prostate cancer: A retrospective cohort study within the FinRSPC trial. July 18, 2025 Unplanned hospitalization among advanced prostate cancer patients by diabetes status-a ...

ASCO 2025, prostate cancer, Metastatic Castration-Resistant Prostate Cancer (mCRPC), XALute Study, Xaluritamig, Cabazitaxel, Xaluritamig versus Cabazitaxel or Second Androgen Receptor-Directed Therapy ...

SNMMI 2025 clinical value of the PROSTest to detect biochemical recurrence in prostate cancer, PSMA-PET/CT, PSMA-PET/CT imaging, PROSTest, biochemical recurrence in prostate cancer.